A capsule’s inactive ingredients can be central to the question someone brings to menopause care. Midi publishes a separate progesterone page that calls its product vegan and peanut-free and names the capsule materials. It also calls the prescription compounded. Those statements need to be read together rather than selecting the reassuring ingredient claim and overlooking the preparation’s regulatory status.

This September 29, 2026 assessment distinguishes that specific offer from Midi’s broader hormone-care service. The reviewed information describes a product and access process; it does not authenticate a dispensed batch or establish an individual’s allergy safety, treatment eligibility or result.

In this article

The store page identifies a distinct compounded product

Midi’s progesterone offer describes oral micronized progesterone and tells patients to ask their clinician about its compounded hormone therapy. It names progesterone micronized powder as the active ingredient. This is a more precise record than a general statement that a menopause service can prescribe hormones.

The page’s terminology should remain attached to this separate offer. It does not mean that every Midi prescription is compounded, nor that every oral progesterone product has this formula. Evernow’s review illustrates a different evidence limit: its public progesterone page establishes relevant care but leaves the dispensed form and manufacturer unanswered. These are differences in documented identity, not a clinical ranking.

Read the peanut-free statement alongside the named excipients

The Midi page lists microcrystalline cellulose and a vegetarian capsule made with hypromellose and water as inactive ingredients. It advertises the preparation as entirely vegan and peanut-free. These are the provider’s product statements; no supplied capsule or independent ingredient assay was inspected for this review.

That distinction matters for a person with an allergy concern. Ask the clinician and dispensing pharmacy to confirm the actual preparation and relevant ingredient information for the order. The capsule-excipient guide helps separate the active hormone, filler and capsule shell. A public list can support a focused inquiry, but it cannot serve as personal permission to take a medicine.

A different formulation does not inherit another product’s approval

The current Prometrium label lists oral micronized progesterone with peanut oil and gelatin. Midi’s separately listed formulation is therefore not established as that same labeled product. Sharing a hormone name does not make the preparation, excipients or evidence package identical.

FDA’s compounding explanation says compounded drugs are not FDA-approved and their safety, effectiveness and quality are not reviewed by the agency before marketing. Compounding can meet particular medical needs, but an ingredient preference does not establish that this option is safer or more effective overall. Ask why the clinician proposes it and which pharmacy and written instructions would accompany the actual prescription.

The medicine’s purpose needs more precision than balancing hormones

Midi’s capsule copy discusses uterine-lining effects, irregular bleeding, sleep and mood. Those descriptions are not interchangeable reasons for prescribing to every person. The clinical question is which specific purpose applies and how the proposed preparation fits the rest of that person’s treatment.

Our progesterone-purpose guide helps organize that conversation. FDA menopause guidance explains both benefits and risks and cautions against assuming compounded bioidentical hormones are safer or more effective. A molecular resemblance to the body’s hormone cannot settle the suitability of the finished capsule. This assessment does not assign a regimen or infer protection across different routes and formulations.

The capsule price and the visit fee purchase different things

The product page starts at $35 for a thirty-day supply, describes out-of-pocket purchase and excludes Arizona from availability. Those limits qualify the offer even though Midi’s broader service markets national access. The precise strength, quantity and selected charge still need confirmation.

Midi’s pricing page separately lists self-pay visits at $250 initially and $150 for return visits. The listed appointments are thirty and fifteen minutes respectively. Insurance cost-sharing varies by plan. A visit benefit cannot be presumed to cover this out-of-pocket compounded product, and the medicine’s starting price does not include every clinical charge. Refund and cancellation terms for the selected capsule were not established here.

Insurance statements include material access restrictions

The HRT service page states that Midi cannot treat Medicaid or Medi-Cal patients, including as self-pay patients. It says Medicare beneficiaries may use self-pay care but cannot submit claims for Midi visits, medicines or related services. These are attributed service conditions, not general rules for every menopause provider.

Those details deserve attention before comparing a headline consultation price. Gennev’s review examines a different physician-and-dietitian service with separate fee categories and plan-specific coverage. Eligibility, benefit verification and product selection must each be resolved for the intended arrangement. A broad insurance logo cannot answer all three questions or override a published program restriction.

Sedating effects deserve follow-up rather than a promise of better sleep

Midi presents sleep and calming effects in its product description. MedlinePlus identifies dizziness and drowsiness with oral progesterone, which makes tolerability a practical discussion even when sleep is among the symptoms being assessed. The provider’s benefit language is not proof of predictable benefit without unwanted effects.

The drowsiness guide and follow-up guide help distinguish questions about daily activities from decisions about the prescription itself. Ask who can address an ingredient concern, a dispensing discrepancy or a troubling effect. The strongest next step in understanding this offer is a clear professional explanation of the exact compounded capsule and its intended role.

Sources for this article

Source type matters. A provider page describes an offer; an exact product label describes that medicine.

  1. Midi: compounded progesterone capsuleProvider exact oral micronized compounded offer; ingredient and vegan/peanut-free statements attributed, no supplied-product assay or personal allergy clearance; Arizona exclusion retained · Checked 2026-09-29
  2. DailyMed: Prometrium progesterone capsulesExact Acertis product labeling updated July23,2026; oral micronized progesterone, peanut oil/gelatin and peanut-allergy restriction, not a label for every provider or generic · Checked 2026-09-29
  3. FDA: Understanding the Risks of Compounded DrugsFederal regulatory explanation; compounded preparations are not FDA-approved, no inference about inspection or quality of a named pharmacy · Checked 2026-09-29
  4. FDA: MenopauseCurrent federal patient guidance; product-dependent benefits/risks and prevention limits, no personal eligibility or class-wide label-change inference · Checked 2026-09-29
  5. Midi: pricing and insuranceProvider consultation units and self-pay prices; plan-dependent insurance and separate out-of-pocket medicine, no selected benefit verification · Checked 2026-09-29
  6. Midi: hormone replacement therapyProvider care and access restrictions, including Medicaid/Medi-Cal and Medicare self-pay conditions; distinct from separate compounded capsule offer · Checked 2026-09-29
  7. MedlinePlus: ProgesteroneFederal medication information; oral-capsule identity, possible dizziness/drowsiness and professional discussion only; public schedules not reproduced as reader instructions · Checked 2026-09-29
How we use evidence ↗